Study Explores HER3-Targeted Therapy Patritumab Deruxtecan as Neoadjuvant Option for Early-Stage Triple-Negative Breast Cancer

A recent study has examined the potential of HER3-targeted therapy using patritumab deruxtecan in improving treatment outcomes for patients with early-stage triple-negative breast cancer (TNBC). Researchers focused on evaluating the efficacy of this neoadjuvant antibody-drug conjugate (ADC) as a means to reduce reliance on traditional chemotherapy and its associated side effects.

Triple-negative breast cancer is an aggressive form of the disease that lacks three common receptors targeted by existing treatments, making it challenging to treat. The study investigated patritumab deruxtecan, which targets HER3—a protein expressed in certain cancers—to determine its effectiveness in shrinking tumors before surgery. By incorporating this targeted approach, researchers aim to minimize the adverse effects often linked to conventional chemotherapy while maintaining or improving therapeutic outcomes. Further details regarding the study’s findings and implications are expected as research progresses.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 31, 2025

Author

GOAI